Cancer Research Technology
Log in Register
Menu

Anti-V(beta)3 T cell receptor (TcR) [JOVI.3]

Invented by Dr Mike Owen at Cancer Research UK London Research Institute: Lincoln's Inn Fields

Info

Catalogue Number 152627
Applications FACS IHC IP Fn
Antigen/Gene or Protein Targets V(beta)3 T cell receptor (TcR)
Reactivity Human
Relevance Monoclonal antibody used in the study of T cell diseases, and as a CAR therapy in T cell lymphoma/leukaemia.

Background and Research Application
The T cell receptor is heterodimer of alpha/beta or gamma/delta chains, expressed on all mature T cells. TCR’s recognise antigen peptides bound to MHC molecules, providing the basis of antigen specific response by T cells.
JOVI.3 can be used for studies of T cell mediated diseases, including autoimmunity and allergy. The antibody recognises any human T cell receptor that has the vß3 region, staining 50-75% % of peripheral blood T cells and T cell lines.
Host Mouse
Immunogen Thymus, spleen and mesenteric lymph nodes isolated from a mouse transgenic for human Vb3 TcR.
Immunogen UniProt ID P09693
Positive Control CD3 positive PBMCs
Subclass IgG2a
Myeloma Used P3/NS1/1-Ag4.1
Recommended Growing Conditions DMEM + 5% FCS
Notes Production Details
Purified using multi-step affinity chromatography with protein A.

Storage Conditions
Store at -20 degrees frozen. Avoid repeated freeze/thaw cycles.

Points of Interest
Antibody JOVI-3 is mitogenic for T cells expressing TCR V beta 3. V beta 3 sequence was chosen because of its reported elevated usage in the synovial T cells of rheumatoid arthritis patients.

This antibody has been combined into a chimeric antigen receptor therapy approach, with the aim to selectively deplete the subset of T cells in T cell lymphomas or leukaemias, whilst leaving the non-reactive T cell subset intact.

Concentration
1mg/ml as standard
Research Area Cell Type or Organelle Marker, Immunology

References

There are 8 reference entries for this reagent.

View All References

References: 8 entries

Viguier et al. 2015. J Invest Dermatol. 135(2):418-24. PMID: 25207820.

Peripheral and local human papillomavirus 16-specific CD8+ T-cell expansions characterize erosive oral lichen planus.

Europe PMC ID: 25207820

San José et al. 1999. J Biol Chem. 274(47):33740-6. PMID: 10559266.

Fn

Receptor engagement transiently diverts the T cell receptor heterodimer from a constitutive degradation pathway.

Europe PMC ID: 10559266

Sahuquillo et al. 1998. J Exp Med. 187(8):1179-92. PMID: 9547330.

IP

T cell receptor (TCR) engagement in apoptosis-defective, but interleukin 2 (IL-2)-producing, T cells results in impaired ZAP70/CD3-zeta association.

Europe PMC ID: 9547330

Viney et al. 1992. Hybridoma. 11(6):701-13. PMID: 1284120.

FACS IHC IP

Generation of monoclonal antibodies against a human T cell receptor beta chain expressed in transgenic mice.

Europe PMC ID: 1284120


Add a reference

References: 8 entries

Viguier et al. 2015. J Invest Dermatol. 135(2):418-24. PMID: 25207820.

Peripheral and local human papillomavirus 16-specific CD8+ T-cell expansions characterize erosive oral lichen planus.

San José et al. 1999. J Biol Chem. 274(47):33740-6. PMID: 10559266.

Fn

Receptor engagement transiently diverts the T cell receptor heterodimer from a constitutive degradation pathway.

Sahuquillo et al. 1998. J Exp Med. 187(8):1179-92. PMID: 9547330.

IP

T cell receptor (TCR) engagement in apoptosis-defective, but interleukin 2 (IL-2)-producing, T cells results in impaired ZAP70/CD3-zeta association.

Viney et al. 1992. Hybridoma. 11(6):701-13. PMID: 1284120.

FACS IHC IP

Generation of monoclonal antibodies against a human T cell receptor beta chain expressed in transgenic mice.


Add a reference